drugset / Trial / NCT07289035

Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.

NCT07289035

Phase 2 Not yet recruiting 35 enrolled Azienda Ospedaliera Universitaria Integrata Verona
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of TMX in adults patients with cystic fibrosis who do not have mutations currently eligible for therapy with modulator drugs. The main questions it aims to answer is: . What medical problems do participants have when taking drug TMX? Participants will: * Take drug TMX every day for 6 months * Visit the clinic once every 28 days for checkups and tests

Timeline

Start
2026-01-15
Primary completion
2026-04-01
Completion
2027-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule 20 mg

Indications